Continuous manufacturing process monitoring of pharmaceutical solid dosage form: A case study.

Continuous manufacturing Multivariate data analysis Process analytical technology Process data analytics Process data science Process monitoring Solid dosage form

Journal

Journal of pharmaceutical and biomedical analysis
ISSN: 1873-264X
Titre abrégé: J Pharm Biomed Anal
Pays: England
ID NLM: 8309336

Informations de publication

Date de publication:
05 Feb 2020
Historique:
received: 20 08 2019
revised: 01 11 2019
accepted: 01 11 2019
pubmed: 28 11 2019
medline: 13 11 2020
entrez: 28 11 2019
Statut: ppublish

Résumé

Continuous Manufacturing (CM) of pharmaceutical drug products is a rather new approach within the pharmaceutical industry. In the presented paper, a GMP continuous wet granulation line used for clinical production of solid dosage forms was investigated with a thorough monitoring strategy regarding process performance and robustness. The line was composed of the subsequent continuous unit operations feeding - twin-screw wet-granulation - fluid-bed drying - sieving and tableting; the formulation of a new pharmaceutical entity in development was selected for this study. In detail, a Design of Experiments (DoE) was used to evaluate the impact of the three main factors (amount of water, filling rate, and shear force in twin-screw granulator) on the tablet quality. The process was monitored via in-process control (IPC) tests (e.g. weight, hardness, disintegration, and loss-on-drying), Process Analytical Technologies (PAT), and through the analysis of the process parameters (multivariate process control). The tested formulation was very robust to the large process variation of the DoE: all IPC results were in specification, the PAT probes provided stable results for the content uniformity and no critical variations can be detected in the process parameters. An adequate monitoring strategy was presented and the robustness of the process with one formulation has been demonstrated. In summary, this continuous process in combination with smart formulation development allows the robust production of constant quality tablets. The synergy between PAT, process data science and IPC creates an adequate monitoring framework of the continuous manufacturing line.

Identifiants

pubmed: 31771809
pii: S0731-7085(19)32037-0
doi: 10.1016/j.jpba.2019.112971
pii:
doi:

Substances chimiques

Excipients 0
Pharmaceutical Preparations 0
Tablets 0
Water 059QF0KO0R

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

112971

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

Yves Roggo (Y)

Novartis Pharma AG, Continuous Manufacturing (CM) Unit, CH-4002, Basel, Switzerland. Electronic address: yves.roggo@novartis.com.

Victoria Pauli (V)

Novartis Pharma AG, Continuous Manufacturing (CM) Unit, CH-4002, Basel, Switzerland.

Morgane Jelsch (M)

Novartis Pharma AG, Continuous Manufacturing (CM) Unit, CH-4002, Basel, Switzerland.

Laurent Pellegatti (L)

Novartis Pharma AG, Continuous Manufacturing (CM) Unit, CH-4002, Basel, Switzerland.

Frantz Elbaz (F)

Novartis Pharma AG, Continuous Manufacturing (CM) Unit, CH-4002, Basel, Switzerland.

Simon Ensslin (S)

Novartis Pharma AG, Continuous Manufacturing (CM) Unit, CH-4002, Basel, Switzerland.

Peter Kleinebudde (P)

Institute of Pharmaceutics and Biopharmaceutics, Heinrich Heine University, Universitaetsstr. 1, 40225, Dusseldorf, Germany.

Markus Krumme (M)

Novartis Pharma AG, Continuous Manufacturing (CM) Unit, CH-4002, Basel, Switzerland.

Articles similaires

Humans Pharmaceutical Preparations Drug Utilization Prescription Drugs
Animals Dietary Fiber Dextran Sulfate Mice Disease Models, Animal
Silicon Dioxide Water Hot Temperature Compressive Strength X-Ray Diffraction
1.00
Oryza Agricultural Irrigation Potassium Sodium Soil

Classifications MeSH